

- 17 Arimoto K, Takahashi H, Hishiki T, et al. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. *Proc Natl Acad Sci USA*. 2007;104:7500-7505.
- 18 Zhao C, Denison C, Huibregtse JM, et al. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. *Proc Natl Acad Sci USA*. 2005;102:10200-10205.
19. Schwer H, Liu LQ, Zhou L, et al. Cloning and characterization of a novel human ubiquitin-specific protease, a homologue of murine UBP43 (Usp18). *Genomics* 2000;65:44-52.
20. Malakhov MP, Malakhova OA, Kim KI, et al. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. *J Biol Chem* 2002;277:9976-9981.
21. Li XD, Sun L, Seth RB, et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. *Proc Natl Acad Sci USA* 2005;102:17717-17722.
22. Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. *Gastroenterology* 2005;129:1031-1041.
23. Asahina Y, Izumi N, Uchihara M, et al. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alpha plus ribavirin and intravenous twice-daily treatment with interferon beta. *Hepatology* 2001;34:377-384.
24. Loo YM, Owen DM, Li K, et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. *Proc Natl Acad Sci USA* 2006;103:6001-6006.

25. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. *Gastroenterology* 2006;130:231-264.
26. National Institute of Health. National Institute of Health Consensus Development Statement: management of hepatitis. *Hepatology* 2002;36(Suppl 1):S3-S20.
27. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. *Gastroenterology* 2005;128:1437-1444.
28. Malakhova OA, Kim KI, Luo JK, et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. *EMBO J* 2006;25:2358-2367.
29. Randall G, Chen L, Panis M, et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. *Gastroenterology* 2006;131:1584-1591.
30. Lanford RE, Guerra B, Lee H, et al. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. *Hepatology* 2006;43:961-972.
31. Asahina Y, Izumi N, Umeda N, et al. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. *J Viral Hepat* 2007;14:396-403.
32. Taylor MW, Tsukahara T, Brodsky L, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. *J Virol* 2007;81:3391-3401.

33. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. *Hepatology* 2007;46:1548-1563.

FIGURE LEGENDS

Figure 1. Comparison of hepatic gene expression levels between chronic hepatitis C patients (n = 74) and non-viral liver disease patients (n = 5). Expression levels of RIG-I, MDA5, LGP2, Cardif, RNF125, ISG15, and USP18 are shown. Error bars indicate the standard error. Upon HCV infection, expression of these genes except Cardif was stimulated. The p values determined by Mann–Whitney U-test between two groups were as follows: RIG-I, 0.02; MDA5, 0.01; LGP2, 0.005; Cardif, 0.7; RNF125, 0.06; ISG15, 0.007; USP18, 0.004.

Figure 2. Comparison of hepatic gene expression levels according to final virological outcome. Expression levels of RIG-I, MDA5, LGP2, ISG15, USP18, Cardif, RNF125, RIG-I/Cardif ratio and RIG-I/RNF125 ratio are shown. Open column indicates SVR (n = 30), gray column indicates TR (n = 24), and closed column indicates NVR (n = 20). Error bars indicate the standard error. The p values were analyzed by the Kruskal–Wallis test.

Figure 3. Receiver operator characteristic (ROC) curve for prediction of non-virological response. ROC curves were generated to compare (A) RIG-I/Cardif ratio (black line) and RIG-I/RNF125 ratio (gray line), (B) RIG-I (black line), MDA5 (gray line), and LGP2 (dotted line), and (C) ISG15 (black line) and USP18 (gray line).

Figure 4. (A) Western blot analysis. Five were SVR (lanes 1–5), four were NVR (lanes 6–9), and three were non-HCV control (lanes 10–12). Specific bands for Cardif and beta-actin are indicated by arrows. (B) Expression level of Cardif protein

normalized to beta-actin in the liver biopsy specimens according to ultimate treatment response. Error bars indicate the standard error.

Figure 5. Transcriptional responses during PEG-IFN alpha-2b and ribavirin therapy in PBMC (n = 14). Open column indicates SVR (n = 7) and closed column indicates NVR (n = 7). Error bars indicate the standard error. The p values determined by Mann–Whitney U-test between two groups at 8 hours were as follows: RIG-I, 0.3; RNF125, 0.3; Cardif, 0.7; ISG15, 0.3; USP18, 0.2.

Supplementary Figure 1. Host antiviral innate defense system proposed by in vitro experiments. Upon viral infection, cytoplasmic viral sensors (RIG-I and MDA5) detect viral pathogens, resulting in IFN beta gene activation via Cardif, an adaptor molecule. RIG-I/MDA5 sensing is negatively regulated by LGP2, a dominant negative viral sensor lacking CARD. RIG-I, MDA5, and Cardif are ubiquitinated by RNF125, a specific E3-ligase, which results in suppression the functions of these molecules via the ubiquitin-proteasome pathway. Cytoplasmic viral sensors and molecules involving IFN signal transduction (Jak1 and STAT1) are ISGylated by ISG15, a ubiquitin-like protein, and this function is suppressed by USP18, a specific protease that remove ISG15 from ISGylated protein. HCV-NS3/4A specifically cleaves Cardif as part of its immune evasion strategy.

Supplementary Figure 2. Comparison of hepatic gene expression levels between SVR and NVR in patients with genotype 2. Open column indicates SVR (n = 5) and closed column indicates NVR (n = 5). Error bars indicate the standard error. The p values were

analyzed by Mann–Whitney U-test (RIG-I, 0.3; MDA5, 0.1; LGP2, ISG15, 0.03; USP18, 0.6; Cardif, 0.03; RNF125, 0.04; RIG-I/Cardif, 0.02; and RIG-I/RNF125, 0.009).

Table 1. Patient characteristics at baseline according to final virological response

	SVR n = 30	TR n = 24	NVR n = 20	p value
Age (y. o.)	52 ± 13	60 ± 8.7	60 ± 10	0.04*
Female % (M/F)	47% (16/14)	63% (9/15)	60% (8/12)	0.5 [†]
Naïve & Relapser [‡] /Non-responder [‡]	26/4	20/4	14/6	0.3 [†]
BMI	24.6 ± 3.0	24.9 ± 4.4	24.0 ± 2.1	0.6*
ALT (IU/L)	75 ± 57	65 ± 35	68 ± 41	1.0*
Hemoglobin (g/dL)	14.3 ± 1.6	14.1 ± 1.1	14.5 ± 1.7	0.6*
Platelet count (×10 ³ /μL)	182 ± 62	169 ± 48	140 ± 39	0.04*
Liver histology				
A1/A2/A3	19/8/3	14/8/1	10/10/0	0.3 [†]
F1/F2/F3	14/9/7	11/7/5	7/5/8	0.7 [†]
Viral load (×10 ⁶ IU/mL)	1.6 ± 1.2	1.8 ± 1.1	1.6 ± 1.1	0.8*
Viral decline rate (log ₁₀ /day)				
First phase	2.1 ± 0.9	1.5 ± 0.6	0.7 ± 0.5	< 0.0001*
Second phase	0.05 ± 0.05	0.04 ± 0.02	0.006 ± 0.008	< 0.0001*

*The p values were determined by Kruskal–Wallis test.

[†]The p values were determined by chi-square test.

[‡]Response to previous IFN treatment

BMI: body mass index

ALT: alanine aminotransferase

Table 2. Area under the ROC curves, sensitivity, specificity, and negative and positive predictive values of non-virological responses

Variables	Az	95% CI	Cut-off	Sensitivity	Specificity	NPV*	PPV†
RIG-I	0.89	0.78–0.95	0.68	0.80	0.87	0.92	0.70
MDA5	0.92	0.86–0.98	0.84	0.82	0.89	0.93	0.74
LGP2	0.76	0.63–0.90	1.03	0.65	0.72	0.85	0.46
RIG-I/Cardif	0.91	0.84–0.99	0.88	0.75	0.91	0.91	0.75
RIG-I/RNF125	0.81	0.69–0.93	1.05	0.82	0.62	0.91	0.43
ISG15	0.91	0.85–0.97	0.36	0.90	0.81	0.96	0.64
USP18	0.90	0.84–0.96	0.67	0.90	0.83	0.96	0.67


*NPV: negative predictive value

†PPV: positive predictive value

Table 3. Multivariate analysis for the factors associated with non-virological response

Variable	Odds Ratio	95% CI	P value
RIG-I/Cardif Ratio (by 0.1)	1.5	1.1–2.1	0.008
RIG-I/RNF125 Ratio (by 0.1)	1.2	1.0–2.5	0.1
ISG15 (by 0.1/internal control)	1.5	1.1–2.0	0.01
Age (by 1 yr)	1.0	0.9–1.1	0.6
Platelet count (by $1 \times 10^4/\mu\text{L}$)	1.2	0.9–1.5	0.07

Figure 1






Figure 2

Figure 3






Figure 4








Figure 5

Supplementary Figure 1 for Online Publish and Review





Supplementary Figure 2 for Online Publish and Review

Smad4 is Essential for Down-regulation of E-cadherin Induced by TGF- β in Pancreatic Cancer Cell Line PANC-1

Shinichi Takano^{1,2}, Fumihiko Kanai³, Amarsanaa Jazag³, Hideaki Ijichi³, Jian Yao⁴, Hideoki Ogawa⁵, Nobuyuki Enomoto², Masao Omata³ and Atsuhito Nakao^{1,5,*}

¹Department of Immunology, ²Department of Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi 409-3898, Japan; ³Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; ⁴Department of Molecular Signaling, Interdisciplinary Graduate School of Medicine and Engineering, and ⁵Atopy Research Center, Juntendo University School of Medicine, Tokyo 113-8421, Japan

Received November 2, 2006; accepted January 9, 2007; published online February 14, 2007

Smad4 is a tumour suppressor gene frequently deleted in pancreatic cancer. To investigate the roles of Smad4 deficiency in invasive and metastatic capabilities of pancreatic cancer, we examined the effects of Smad4 deficiency on regulation of the invasion suppressor E-cadherin in pancreatic cancer cell line PANC-1. TGF- β decreased expression of E-cadherin and β -catenin proteins at the plasma membrane, increased Snail and Slug mRNA expression, and induced fibroblastoid morphology in PANC-1 cells. These effects of TGF- β were abrogated in Smad4-knocked-down PANC-1 cells. We also found that TGF- β -induced down-regulation of E-cadherin expression was partially inhibited in Snail- and Slug-knocked-down PANC-1 cells. Thus, Smad4 mediates down-regulation of E-cadherin induced by TGF- β in PANC-1 cells, at least in part, through Snail and Slug induction. These results suggest that Smad4 deficiency observed in invasive and metastatic pancreatic cancer might not be linked to the loss of E-cadherin.

Key words: pancreatic cancer, E-cadherin, Smad4, TGF- β .

Abbreviations: TGF- β , transforming growth factor- β ; VEGF, vascular endothelial growth factor; siRNA, small-interfering RNA; EMT, epithelial mesenchymal transition.

Smad4 was originally identified as a tumour suppressor gene (DPC4: deleted in pancreatic cancer, locus 4) functionally inactivated in one-half of pancreatic adenocarcinoma (1). Subsequent studies have revealed that Smad4 belongs to the Smad gene family, which encodes intracellular signalling mediator of the transforming growth factor- β (TGF- β) superfamily of cytokines (2, 3). TGF- β binds to two different types of serine/threonine kinase receptors, termed type I and type II. The activated heteromeric complex of TGF- β type I and type II receptors induces phosphorylation of Smad2 and Smad3, which form hetero-oligomeric complexes with Smad4. The complexes then translocate to the nucleus and regulate transcriptional responses together with DNA binding co-factors.

Since TGF- β is a potent inhibitor of the growth of epithelial cells (4), the tumour-suppressor function of Smad4 in pancreatic cancer has been attributed to its capacity to mediate TGF- β -induced growth inhibition. However, recent studies propose that loss of Smad4 may be associated with invasive and metastatic capabilities of the tumour through various mechanisms (5–8). For example, Schwarte-Waldhoff *et al.* (7) reported that Smad4-deficient pancreatic cancer cells showed increased vascular endothelial growth factor (VEGF) expression

associated with their capabilities of *in vivo* metastasis through enhanced angiogenesis.

E-cadherin is a 120 kDa transmembrane glycoprotein that connects cells via homotypic interactions (9). Its cytoplasmic domain associates with a family of submembranous cytoplasmic proteins termed the catenins: α -catenin, β -catenin, γ -catenin and p120 (10). They link E-cadherin to the cytoskeleton, thus acting as a scaffold for the maintenance of cell architecture. The E-cadherin-catenin complexes represent the main adhesion system responsible for the maintenance of cell–cell contacts in epithelial tissues (10).

It is now recognized that E-cadherin may act as a tumour suppressor (11). Numerous studies have shown that down-regulation of E-cadherin expression or functional perturbation of the E-cadherin-catenin complexes has been found to occur very frequently during the progression of carcinomas and is associated with an invasive and metastatic phenotype of the tumours. Regarding pancreatic cancer, loss of membranous E-cadherin expression was associated with high grade and advanced stage of the cancer (12–14). Furthermore, Perl *et al.* (15) elegantly showed that the loss of E-cadherin expression coincided with the transition from well differentiated adenoma to invasive carcinoma in a transgenic mouse model of pancreatic β -cell carcinogenesis, giving further support for a role of E-cadherin as an 'invasive suppressor' of pancreatic cancer.

In this study, we therefore hypothesized that loss of Smad4 might be linked to down-regulation of the

*To whom correspondence should be addressed. Tel: +81-55-273-6752, Fax: +81-55-273-9542, E-mail: anakao@yamanashi.ac.jp

invasive suppressor E-cadherin in pancreatic cancer cells, resulting in acquisition of highly metastatic capabilities of the tumour. Contrary to our expectations, the current results using Smad4-knockdown pancreatic cancer cell lines suggest that Smad4 is essential for down-regulation of E-cadherin induced by TGF- β in pancreatic cancer cell lines and Smad4 deficiency may not be associated with selective loss of E-cadherin observed in advanced pancreatic cancer.

MATERIALS AND METHODS

Cell Lines—The Grade III undifferentiated human pancreatic cancer cell line, PANC-1 (16), was purchased from the American Type Culture Collection (Rockville, MD, USA). Human pancreatic adenocarcinoma cell lines PK-8 and PK-9 were obtained from Dr M. Kobari (Sendai, Japan) (17). Human keratinocyte cell line HaCaT cells were previously obtained from Dr N.E. Fusenig (DKFZ, Heidelberg, Germany) (18). These cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Gibco/Invitrogen, Carlsbad, CA) containing 10% FCS and 100 μ g/ml streptomycin.

Establishment of Smads-knocked-down Cell Lines—We have established Smad2-knocked-down, Smad3-knocked-down, Smad4-knocked-down PANC-1 cells and control Smad4-intact PANC-1 cells, which are designated PANC-1-S2KD, PANC-1-S3KD, PANC-1-S4KD and PANC-1-puro, by using the stable RNA interference (RNAi) method as previously described (19, 20). PK-8 and HaCaT cells stably transfected with the plasmid expressing siRNA that targeted Smad4 (S4KD) or with the empty plasmid (puro) were also established as previously described (19, 20).

Reagents—Human recombinant TGF- β 1 was purchased from R&D Inc. (Minneapolis, MN, USA). PD98059, SB203580 and LY294002 were purchased from CALBIOCHEM (San Diego, CA, USA) and SB202190, SP600125 were purchased from Biomol Research Laboratories, Inc. (Plymouth Meeting, PA, USA). Human Snail and Slug siRNA were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Transfection of Snail and Slug siRNAs into PANC-1 cells was performed according to the manufacturer's instruction.

Western Blot—Western blot analysis was performed by using antibodies for E-cadherin (Beckton Dickinson, San Jose, CA, USA), Smad2/3, Smad4 (Transduction Laboratories Inc.) and β -actin (Cell Signaling Technology Inc., Beverly, MA, USA) as previously described (19, 20).

Immunofluorescence—Cells were grown to confluency on 8-well chamber slides, rinsed with PBS and fixed with ice-cold 100% methanol for 5 min at -20°C . The fixed cells were incubated with primary antibody, anti human E-cadherin (dilution 1:50 in PBS + 1% BSA) (Beckton Dickinson) for 1 h followed by FITC secondary antibodies (dilution 1:50 in PBS + 1% BSA) (Dako Cytomation, Kyoto, Japan). Samples were mounted with mounting medium (Dako Cytomation) and examined under an ultraviolet light microscope.

Quantitative Real-time PCR—Quantitative real-time PCR with specific primers and probes (purchased from Applied Biosystems) was performed using the ABI7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA) as previously described (19, 20).

ELISA—Cells were cultured in serum-free DMEM for indicated times and the amounts of TGF- β 2 and VEGF in the culture supernatants were determined by using the human TGF- β 2 and VEGF ELISA kit (R&D Inc.).

Data Analysis—Values represent the mean \pm SD of triplicate samples per group. An unpaired Student's *t*-test was used for the statistical analysis of the results. $P < 0.05$ was considered to be significant.

RESULTS

Smad4 Deficiency Attenuates Down-regulation of E-cadherin Induced by TGF- β in Human Pancreatic Carcinoma Cell Line PANC-1—The human pancreatic carcinoma cell line, PANC-1, expressed functional TGF- β type I and II receptors and Smads (21–23). In addition, Nakajima *et al.* (24) recently reported that TGF- β decreased E-cadherin expression in PANC-1 cells with a change to a fibroblastoid morphology (24). Consistent with these findings, Western blot and immunofluorescence study showed that control PANC-1-puro cells expressed E-cadherin, which was down-regulated by addition of TGF- β (Fig. 1A and B). PANC-1-puro cells also showed a change from epithelial to spindle fibroblastic shaped morphology upon TGF- β stimulation (Fig. 1B). We also found significant β -catenin expression at the plasma membrane in PANC-1-puro cells, which was down-regulated by TGF- β (Fig. 1B). In contrast, treatment with TGF- β did not affect E-cadherin expression, epithelial morphology, and β -catenin expression at the plasma membrane in Smad4-knocked-down PANC-1-S4KD cells (Fig. 1A and B). These results indicated that Smad4 is essential for TGF- β -induced down-regulation of E-cadherin in PANC-1 cells.

Smad4 Deficiency Attenuates Down-regulation of E-cadherin Induced by TGF- β in PK-8, PK-9 and HaCaT Cell Lines—To determine whether Smad4 is essential for TGF- β -induced down-regulation of E-cadherin in other cell lines, we examined the effect of Smad4 deficiency on TGF- β -induced down-regulation of E-cadherin in human pancreatic cancer cell line PK-8 and human keratinocyte cell line HaCaT. Both cell lines express Smad4 and respond to TGF- β (25, 26). Similar to the results obtained in PANC-1 cells, immunofluorescence study showed that TGF- β down-regulated E-cadherin expression in control, but not in Smad4-knocked-down, PK-8 and HaCaT cells (Fig. 2A and B). We also found that PK-9 human pancreatic cancer cell line, which lacked Smad4 expression (25), expressed E-cadherin, which was not affected by stimulation with TGF- β (Fig. 2C). These results suggest that an essential role of Smad4 in TGF- β -induced down-regulation of E-cadherin is not specific to PANC-1 cells and may be a general phenomenon.

Smad4 Deficiency Attenuates TGF- β -induced Expression of Snail and Slug mRNAs in PANC-1 Cells—Transcriptional repression mechanisms have emerged




Fig. 1. Smad4 deficiency attenuates down-regulation of E-cadherin induced by TGF-β in human pancreatic carcinoma cell line PANC-1. Smad4-knockdown PANC-1 cells (PANC-1-S4KD) and control Smad4-intact PANC-1 cells (PANC-1-puro) were established as described in the section 'Materials and Methods'. (A) Cells were stimulated with 10 ng/ml TGF-β for 3 or 6 days and, then, cell lysates were subjected to Western blot analysis with specific antibodies for E-cadherin, Smad4 and β-actin. (B) (Upper panels) Phase contrast microphotographs showing morphology of a representative PANC-1-puro and PANC-1-S4KD cells in response to 72h stimulation of 10 ng/ml TGF-β1; (middle and bottom panels) cells were stimulated with 10 ng/ml TGF-β for 72h and, then, were subjected to immunofluorescence analysis with specific antibodies for E-cadherin and β-catenin. Similar results were obtained at least in three independent experiments.

as one of the crucial processes for the down-regulation of E-cadherin expression during development and tumour progression (27). Several E-cadherin transcriptional repressors have been characterized (Snail, E12/E47, ZEB-1, SIP-1 and Slug) and shown to act through an interaction with proximal E-boxes of the E-cadherin promoter (27-29). Recently, TGF-β was reported to be a regulator of Snail and Slug expression and involved in down-regulation of E-cadherin (30, 31). We thus examined the effects of Smad4 deficiency on Snail and Slug expression in PANC-1 cells. As shown in Fig. 3A, real-time PCR analysis showed that expression of Snail and Slug mRNA was induced by TGF-β in PANC-1-puro cells. Induction of Snail mRNA by TGF-β was observed in the presence of cyclohexamide (CHX), suggesting that *de novo* protein synthesis is not required for the Snail mRNA induction (Fig. 3A). On the other hand, Slug mRNA expression was increased in the presence of CHX alone and TGF-β did not up-regulate Slug mRNA




Fig. 2. Smad4 deficiency attenuates down-regulation of E-cadherin induced by TGF-β in human pancreatic carcinoma cell lines PK-8 and PK-9 and in human keratinocyte cell line HaCaT. Smad4-knockdown PK-8 cells and HaCaT cells (PK-8-S4KD, HaCaT-S4KD) and control Smad4-intact PK-8 and HaCaT cells (PK-8-puro, HaCaT-puro) were established as described in the section 'Materials and Methods'. PK-8-puro or PK-8-S4KD (A), HaCaT-puro or HaCaT-S4KD (B), or Smad4-deficient PK-9 cells (C) were stimulated with 10 ng/ml TGF-β for 3 days and, then, were subjected to immunofluorescence analysis with specific antibodies for E-cadherin and β-catenin. Similar results were obtained at least in three independent experiments.

expression in the presence of CHX. Thus, *de novo* protein synthesis may be required for the Slug mRNA induction (Fig. 3A). In PANC-1-S4KD cells, TGF-β-induced Snail and Slug expression was abrogated (Fig. 3B). To determine whether TGF-β/Smad4-dependent Snail and Slug expression is required for TGF-β-induced down-regulation of E-cadherin, we examined the effects of Snail or Slug deficiency on TGF-β-induced down-regulation of E-cadherin in PANC-1 cells. As shown in Fig. 4A and B, TGF-β-induced down-regulation of E-cadherin was partially suppressed in Snail- and Slug-knocked-down PANC-1 cells. These results suggest that TGF-β/Smad4-dependent Snail and Slug expressions are, at least in part, required for TGF-β-induced down-regulation of E-cadherin in PANC-1 cells.

Smad4 Deficiency Attenuates TGF-β-induced TGF-β and VEGF Production in PANC-1 Cells—Previous studies have suggested that Smad4 deficiency augments TGF-β and VEGF production of pancreatic cancer cells,




Fig. 3. Smad4 deficiency attenuates TGF-β-induced expression of Snail and Slug mRNAs in PANC-1 cells. (A) cDNAs were obtained from PANC-1-puro after 6 h stimulation with 10 ng/ml TGF-β in the presence or absence of 10 μg/ml cyclohexamide (CHX). Then, real-time PCR was performed using specific primers for Snail, Slug, and GAPDH. (B) cDNAs were obtained from PANC-1-puro and PANC-1-S4KD cells after 6 h stimulation with 10 ng/ml TGF-β and, then, real-time PCR was performed using specific primers for Snail, Slug, and GAPDH. The ratio of each gene to that of GAPDH was calculated, and the value of 1.0 was assigned to the PANC-1 wild-type cells that were incubated without TGF-β1. Values represent the mean ± SD of triplicate samples per group. **P* < 0.05 compared with corresponding control. Similar results were obtained at least in three independent experiments.

which is associated with invasive and metastatic capabilities of pancreatic cancer cells (7, 8). Thus, we further examined the effects of Smad4 deficiency on TGF-β and VEGF production in PANC-1 cells (Fig. 5). Real-time PCR analysis showed that Smad7 mRNA induction, which was dependent of Smad4 (32), was abolished in PANC-1-S4KD cells, confirming the specific-knockdown of Smad4 in the cells. TGF-β1 significantly induced TGF-β1 and TGF-β2 mRNA expression in PANC-1-puro cells whereas it was abrogated in PANC-1-S4KD cells. In addition, ELISA assay showed that TGF-β-induced VEGF production was partially, but significantly, suppressed in PANC-1-S4KD cells (Fig. 5B). These results indicated that Smad4 is involved in TGF-β-induced TGF-β and VEGF expression in PANC-1 cells.

Smad3, but not Smad2, Deficiency Attenuates Down-regulation of E-cadherin Induced by TGF-β in PANC-1— Finally, we examined the effects of deficiency of other




Fig. 4. Snail and Slug deficiency partially attenuates TGF-β-induced down-regulation of E-cadherin expression in PANC-1 cells. (A) PANC-1 cells were transfected with Snail, Slug, or control siRNAs according to the manufacturer's instruction. At 72 h after the transfection, cells were stimulated with 10 ng/ml TGF-β for 3 days and, then, cell lysates were subjected to western blot analysis with specific antibodies for E-cadherin and β-actin. (B) The density of the detected bands (E-cadherin and β-actin) was quantified in a Chemi Doc XRS-J, and the ratio (E-cadherin/β-actin) was calculated and presented below the western blot panel.

Smads or non-Smad pathways on down-regulation of E-cadherin induced by TGF-β in PANC-1 cells. As shown in Fig. 6A, Smad2-knockdown and Smad3-knockdown PANC-1 cells showed reduced expression of Smad2 and Smad3. Smad3, but not Smad2, deficiency attenuated down-regulation of E-cadherin induced by TGF-β in PANC-1 cells. In addition, an ERK inhibitor PD98059 and a p38 inhibitor SB203580 marginally suppressed down-regulation of E-cadherin induced by TGF-β in PANC-1 cells (Fig. 6B). In contrast, a JNK inhibitor SP600125 and a PI3K inhibitor LY294002 did not affect down-regulation of E-cadherin induced by TGF-β in PANC-1 cells (Fig. 6B). It was shown that SB203580 (a p38 inhibitor) was not completely specific to p38 and it also inhibited TGF-β signaling (33). Therefore, we examined the effects of SB202190, another selective p38 kinase inhibitor, on the down-regulation of E-cadherin induced by TGF-β in PANC-1 cells. SB202190 did not affect TGF-β-induced decrease of E-cadherin expression (Fig. 6B). These results suggested that Smad3 was also necessary for down-regulation of E-cadherin induced by TGF-β in PANC-1 cells and the ERK pathway was only partially involved in the regulation of E-cadherin.

DISCUSSION

Recent studies suggest that loss of Smad4 may enhance tumourgenicity by mechanisms independent of growth